Search Result

Results for "

Aurora+kinase+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (7) Aurora Kinase (35) Autophagy (3) CDK (3) FAK (1) FLT3 (1) p38 MAPK (1) PERK (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3)
By Research Areas:	Cancer (35)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent *aurora kinase* inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, *aurora-A* and *aurora-B*, respectively .

HY-10179

Danusertib 5+ Cited Publications PHA-739358	Aurora Kinase Autophagy	Cancer
Danusertib is a pyrrolo-pyrazole and *aurora kinase* inhibitor with IC₅₀ of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-13253

AMG 900 4 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-14711

Reversine Maximum Cited Publications 16 Publications Verification	Aurora Kinase Autophagy	Cancer
Reversine is a novel class of ATP-competitive *Aurora kinase* inhibitor with IC₅₀s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.

HY-10128

ZM-447439 5+ Cited Publications	Aurora Kinase Apoptosis	Cancer
ZM-447439 is an *aurora* kinase inhibitor with IC₅₀s of 110 and 130 nM for aurora A and B, respectively.

HY-12003

SNS-314 mesylate 3 Publications Verification	Aurora Kinase	Cancer
SNS-314 mesylate is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-10804

CCT 137690 1 Publications Verification	Aurora Kinase Apoptosis	Cancer
CCT 137690 is a potent and orally available *aurora* kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.

HY-112355

Aurora kinase inhibitor-2	Aurora Kinase	Cancer
Aurora kinase inhibitor-2 is a selective and ATP-competitive *Aurora kinase* inhibitor with IC₅₀s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .

HY-112373

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective **Aurora A kinase** inhibitor with an IC₅₀ of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .

HY-10178

PHA-680632	Aurora Kinase	Cancer
PHA-680632 is an *aurora* kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and *Aurora kinase* inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-12049

CCT129202	Aurora Kinase	Cancer
CCT129202 is an *aurora* kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.

HY-144991

Aurora kinase inhibitor-8	Aurora Kinase	Cancer
Aurora kinase inhibitor-8 is a highly selective inhibitor of the **Aurora kinases**.

HY-162470

DBPR728	Aurora Kinase	Cancer
DBPR728 is an acyl prodrug of 6K465 that carries fewer hydrogen bond donors. 6K465 acts as an *Aurora* kinase inhibitor that destabilizes MYC family cancer proteins and has antitumor efficacy. DBPR728 has the potential to inhibit cancers that overexpress C-MYC and N-MYC, with a 10-fold increase in oral bioavailability compared to 6K465 .

HY-147703

Aurora kinase inhibitor-9	Aurora Kinase	Cancer
Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC₅₀s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .

HY-149693

Aurora kinase inhibitor-11	Aurora Kinase	Cancer
Aurora kinase inhibitor-11 (compound 25) is an inhibitor of Aurora Kinase with an IC₅₀ of 0.14 μM. Aurora kinase inhibitor-11 has anticancer activity .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of **Aurora kinases with IC₅₀** values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-108344

SNS-314	Aurora Kinase	Cancer
SNS-314 is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-175866

Aurora kinase-IN-8	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-8 is a orally active *Aurora kinase* inhibitor. Aurora kinase-IN-8 shows IC₅₀ values of 2.8 and 28.1 nM against **Aurora A kinase and Aurora B kinase*. Aurora* kinase-IN-8 can prevent spindle formation, cause G2/M phase arrest, and induce cell apoptosis. Aurora kinase-IN-8 can be used for the research of cancer, such as triple-negative breast cancer .

HY-147993

Aurora kinase inhibitor-10	Aurora Kinase	Cancer
Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC₅₀ of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .

HY-149694

Aurora kinase inhibitor-12	Aurora Kinase	Cancer
Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of **aurora kinase** which is a key enzyme that is implicated in tumor growth .

HY-169505

Aurora kinase inhibitor-13	Aurora Kinase	Cancer
Aurora kinase inhibitor-13 (Compound 2) is an inhibitor of **Aurora kinase, with an IC₅₀** value of 2.3 μM against Aurora kinase A .

HY-N3737

Derrone	Aurora Kinase PERK Reactive Oxygen Species (ROS)	Cancer
Derrone, a prenylated isoflavones, is an *Aurora kinase* inhibitor, with IC₅₀ values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity .

HY-10320G

Doramapimod (GMP) BIRB 796 (GMP)	p38 MAPK	Cancer
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC₅₀s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity .

HY-113894

Retreversine	Aurora Kinase	Cancer
Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor .

HY-123697

VE-465	Aurora Kinase	Cancer
VE-465 is an *Aurora kinase* inhibitor. VE-465 induces cancer cell apoptosis. VE-465 has anticancer effects in multiple tumor models .

HY-10179R

Danusertib (Standard) PHA-739358 (Standard)	Reference Standards Aurora Kinase Autophagy	Cancer
Danusertib (Standard) is the analytical standard of Danusertib. This product is intended for research and analytical applications. Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-122370A

Tripolin B	Aurora Kinase	Cancer
Tripolin B is an ATP-competitive *Aurora kinase* inhibitor with IC₅₀ values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. Tripolin B does not inhibit Aurora kinase in cells .

HY-160447

*FAK/Aurora* kinase-IN-1**	Aurora Kinase FAK	Cancer
FAK/Aurora kinase-IN-1 is a FAK and *aurora kinase* inhibitor with IC₅₀ values of 6.61 nM and 0.91 nM, respectively. FAK/Aurora kinase-IN-1 shows anticancer effects (WO2018019252A1; compound 11) .

HY-15812

XMD-12	Aurora Kinase	Cancer
XMD-12 (compound 1) is an Aurora kinase (Aurora Kinase) inhibitor with anti-tumor activity that promotes paclitaxel (HY-B0015) induced cell death. XMD-12 exhibits high selectivity and potency against Aurora A, B, and C kinases, with IC₅₀ values of 5.6, 18.4, and 24.6 nM, respectively .

HY-170812

*BET/Aurora* kinase-IN-1**	Aurora Kinase	Cancer
BET/Aurora kinase-IN-1 (Compound 38) is a dual BET/Aurora kinase inhibitor. BET/Aurora kinase-IN-1 shows antiproliferative activities on diverse cancer cell lines and favorable antitumor efficacy in renal cell cancer and colon cancer xenograft models with tumor growth inhibition (TGI) of 45.99% and 53.06%, respectively .

HY-150592

Aurora kinase-IN-2	Aurora Kinase	Cancer
Aurora kinase-IN-2 (compound 12Aj) is a potent *Aurora kinase* inhibitor with IC₅₀ values of 90 and 152 nM for Aurora A and Aurora B. Aurora kinase-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora kinase-IN-2 can be used for cancer research .

HY-123279

OM137	Aurora Kinase CDK	Cancer
OM137 is an *aurora kinase* inhibitor, with an IC₅₀ of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC₅₀ of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes .

HY-10128R

ZM-447439 (Standard)	Aurora Kinase Reference Standards Apoptosis	Cancer
ZM-447439 (Standard) is the analytical standard of ZM-447439 (HY-10128). This product is intended for research and analytical applications. ZM-447439 is an aurora kinase inhibitor with IC50s of 110 and 130 nM for aurora A and B, respectively.

HY-181082

Aurora kinase-IN-10	Aurora Kinase	Cancer
Aurora kinase-IN-10 is an *Aurora kinase* inhibitor. Aurora kinase-IN-10 exhibits IC₅₀ values of 5.94 nM and 86.06 nM against Aurora A and Aurora B, respectively. Aurora kinase-IN-10 has anti-tumor activity and can be used in the research of tumors such as triple-negative breast cancer .

HY-10329R

JNJ-7706621 (Standard)	Reference Standards Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 (Standard) is the analytical standard of JNJ-7706621 (HY-10329). This product is intended for research and analytical applications. JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively .

Derrone	Infection Monophenols Flavonoids Phenols Maclura pomifera (Raf.) Schneid. Plants Moraceae Disease Research Fields Isoflavones Source Classification	Aurora Kinase PERK Reactive Oxygen Species (ROS)
Derrone, a prenylated isoflavones, is an *Aurora kinase* inhibitor, with IC₅₀ values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Aurora+kinase+inhibitor

Inhibitors & Agonists

NaturalProducts

Natural
Products